1
|
Kang N, Zhang X, Wang Z, Dai Y, Lu S, Su W, Gai F, Zhu C, Shen D, Wang J. Validation of a one-step genomics-based molecular classifier for endometrial carcinoma in a large Chinese population. Pathol Res Pract 2024; 254:155152. [PMID: 38277742 DOI: 10.1016/j.prp.2024.155152] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/14/2023] [Revised: 01/08/2024] [Accepted: 01/17/2024] [Indexed: 01/28/2024]
Abstract
OBJECTIVE The aim of this study is to delineate the molecular classification features within Chinese endometrial cancer (EC) patients and to evaluate the concurrence between two widely employed methods for diagnosing EC molecular subtypes. METHODS This retrospective observational cohort study encompassed 479 cases of EC for analysis. Utilizing next-generation sequencing (NGS) panels targeting POLE, TP53, and microsatellite instability (MSI) status, four subtypes [POLE ultramutated (POLE mut), MMR-deficient (MMRd), p53 abnormal (p53abn), and no specific molecular profile (NSMP)] were classified. Immunohistochemistry (IHC) was employed to ascertain the expression of p53 and MMR proteins. RESULTS Among the 479 patients, the distribution of EC subtypes was as follows: 28 (5.85%) POLE mut, 67 (13.99%) MMRd, 60 (12.53%) p53abn, and 324 (67.64%) NSMP. When compared to published findings on EC subtypes in the Caucasian population, our real-world data on Chinese ECs revealed a notably higher proportion of NSMP/CNL (copy number low). The evaluation of MSI/MMR status through NGS-based and IHC-based methods displayed substantial concordance (Kappa = 0.91). Slight discordance between the two techniques in identifying p53 abnormalities (Kappa = 0.83) might stem from TP53 truncating mutations, cytoplasmic p53 expression, null TP53 mutants, and well-documented challenges in interpreting p53 IHC. CONCLUSIONS Chinese ECs exhibit distinctive molecular attributes. For accurate molecular subtyping of Chinese ECs, additional molecular markers that align with the Chinese population's characteristics should be incorporated into existing classifiers. The study's outcomes underscore a strong agreement between NGS and IHC in TP53/p53 detection and MSI assessment.
Collapse
Affiliation(s)
- Nan Kang
- Department of Pathology, Peking University People's Hospital, Beijing, China
| | - Xiaobo Zhang
- Department of Pathology, Peking University People's Hospital, Beijing, China
| | - Zhiqi Wang
- Department of Gynecologic, Peking University People's Hospital, Beijing, China
| | - Yibo Dai
- Department of Gynecologic, Peking University People's Hospital, Beijing, China
| | - Shanshan Lu
- Department of Pathology, Peking University People's Hospital, Beijing, China
| | - Wenqing Su
- Department of Transational Medicine, Amoy Diagnostics Co, Ltd, Xiamen, China
| | - Fei Gai
- Department of Transational Medicine, Amoy Diagnostics Co, Ltd, Xiamen, China
| | - Changbin Zhu
- Department of Transational Medicine, Amoy Diagnostics Co, Ltd, Xiamen, China
| | - Danhua Shen
- Department of Pathology, Peking University People's Hospital, Beijing, China.
| | - Jianliu Wang
- Department of Gynecologic, Peking University People's Hospital, Beijing, China.
| |
Collapse
|
2
|
Wang Z, Li L, Wang Y, Li X, Xu Y, Wang M, Liang L, Wu X, Tang M, Li Y, He S, Du J, He L, Sun M, Yang L, Di J, Gai F, Liu D. Sputum cell-free DNA for detection of alterations of multiple driver genes in lung adenocarcinoma. Cancer Cytopathol 2023; 131:110-116. [PMID: 36103360 DOI: 10.1002/cncy.22644] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/26/2022] [Revised: 06/17/2022] [Accepted: 07/11/2022] [Indexed: 02/07/2023]
Abstract
BACKGROUND Sputum cell-free DNA (cfDNA) has been confirmed to be a valued surrogate sample for detection of EGFR mutations in patients with lung adenocarcinoma (LAC). Whether it is suitable for detection of mutations of multiple driver genes has not been reported. METHODS A total of 83 patients with LAC were enrolled and their sputum and paired tumor samples were collected. A next-generation sequencing (NGS)-based 10-gene panel was used to test sputum supernatant-derived cfDNA and paired tumor DNA. The sputum sediments were used for cytological evaluation. RESULTS The total positive rates of hotspot mutations of the 10 driver genes in sputum cfDNA and matched tissue samples were 65.1% and 77.1%, respectively. The overall detection sensitivity of variants in sputum cfDNA was 81.3% (95% confidence interval [CI], 69.2%, 89.5%) and the specificity was 100% (95% CI, 79.1%, 100%). The sensitivities of testing sputum cfDNA from patients with stage IIIB-IV was 87.0% (95% CI, 74.5%, 94.1%); the sensitivities of testing sputum cfDNA from patients with malignant sputum was 92.3% (95% CI, 78.0%, 98.0%); and the sensitivity of testing sputum cfDNA from patients with malignant sputum in stage IIIB-IV were 94.1% (95% CI, 78.9%, 99.0%). CONCLUSIONS This study demonstrated that sputum cfDNA were successfully used for the detection of multiple driver genes by NGS. Sputum cfDNA could be a valuable surrogate clinical sample for all-in-one test of mutations to guide target therapies, especially for patients with advanced LAC and malignant sputum.
Collapse
Affiliation(s)
- Zheng Wang
- Department of Pathology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Science, Beijing, People's Republic of China
| | - Lin Li
- Department of Oncology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Science, Beijing, People's Republic of China
| | - Yifei Wang
- Department of Pathology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Science, Beijing, People's Republic of China
| | - Xiaoguang Li
- Department of Minimally Invasive Tumor Therapies Center, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Science, Beijing, People's Republic of China
| | - Yan Xu
- Department of Respiratory and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, People's Republic of China
| | - Mengzhao Wang
- Department of Respiratory and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, People's Republic of China
| | - Li Liang
- Department of Cancer Chemotherapy and Radiation Sickness, Peking University Third Hospital, Beijing, People's Republic of China
| | - Xiaonan Wu
- Department of Oncology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Science, Beijing, People's Republic of China
| | - Min Tang
- Department of Oncology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Science, Beijing, People's Republic of China
| | - Yuanming Li
- Department of Minimally Invasive Tumor Therapies Center, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Science, Beijing, People's Republic of China
| | - Shurong He
- Department of Pathology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Science, Beijing, People's Republic of China
| | - Jun Du
- Department of Pathology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Science, Beijing, People's Republic of China
| | - Lei He
- Department of Pathology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Science, Beijing, People's Republic of China
| | - Mingjun Sun
- Department of Pathology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Science, Beijing, People's Republic of China
| | - Li Yang
- Department of Pathology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Science, Beijing, People's Republic of China
| | - Jing Di
- Department of Pathology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Science, Beijing, People's Republic of China
| | - Fei Gai
- Amoy Diagnostics Co, Ltd, Xiamen, People's Republic of China
| | - Dongge Liu
- Department of Pathology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Science, Beijing, People's Republic of China
| |
Collapse
|
3
|
Long C, Li K, Liu Z, Zhang N, Xing X, Xu L, Gai F, Che N. Real-world analysis of the prognostic value of EGFR mutation detection in plasma ctDNA from patients with advanced non-small cell lung cancer. Cancer Med 2023; 12:7982-7991. [PMID: 36621813 PMCID: PMC10134383 DOI: 10.1002/cam4.5582] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/30/2022] [Revised: 11/21/2022] [Accepted: 12/16/2022] [Indexed: 01/10/2023] Open
Abstract
BACKGROUND The plasma sample has emerged as a promising surrogate sample for EGFR mutation detection in advanced non-small cell lung cancer (NSCLC). In clinical practice, whether EGFR variants in baseline plasma ctDNA of advanced NSCLC can predict prognosis in addition to guiding targeted therapy remains to be further explored. MATERIAL AND METHODS In total, 315 NSCLC patients were retrospectively enrolled. EGFR mutation data from tissue detected by ARMS-PCR and paired plasma samples within 1 month of admission detected by SuperARMS or ARMS-PCR were collected. The correlation between baseline plasma ctDNA EGFR mutation status and survival was compared. RESULTS EGFR mutation detection rates in tumor samples and plasma samples were 65.1% (205/315) and 43.8% (138/315). Referred to tissue results, the consistent rate of test ctDNA EGFR alteration by SuperARMS was higher than that detected by ARMS (79.5% vs. 69.0%, p = 0.04), either in stage I-IIIA patients (85.7% vs. 50.0%, p = 0.4) or stage IIIB-IV patients (79.1% vs. 69.4%, p = 0.04). Patients' treatment status and pathological subtype were the two factors that affected plasma ctDNA EGFR alteration detection accuracy. The concordance in non-adenocarcinoma patients was obviously higher than that in adenocarcinoma (p = 0.02), and the concordance in treatment naïve patients was significantly higher than that in relapse patients (p = 0.047). In treatment naïve patients, the median PFS (mPFS) in plasma ctDNA EGFR-positive patients was shorter than that in plasma ctDNA EGFR negative patients (7.0 vs. 10.0 months, p = 0.01). In relapsed patients, the mPFS in plasma ctDNA EGFR-positive patients was 9.0 months versus 11.0 months in plasma ctDNA EGFR negative patients (p = 0.1). CONCLUSIONS A plasma sample could be an alternative for a molecular test when tissue samples was unavailable. The SuperARMS-PCR detection method has high sensitivity in real-world clinical practice. Furthermore, in patients with stage IIIB-IV, baseline plasma ctDNA EGFR mutation positivity not only guides targeted therapy but also predicts a worse prognosis.
Collapse
Affiliation(s)
- Chaolian Long
- Department of Pathology, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China
| | - Kun Li
- Department of Pathology, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China
| | - Zichen Liu
- Department of Pathology, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China
| | - Nana Zhang
- Department of Pathology, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China
| | - Xuya Xing
- Department of Pathology, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China
| | - Liming Xu
- Amoy Diagnostics Co., Ltd, Xiamen, China
| | - Fei Gai
- Amoy Diagnostics Co., Ltd, Xiamen, China
| | - Nanying Che
- Department of Pathology, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China
| |
Collapse
|
4
|
Han X, Tang X, Zhu H, Zhu D, Zhang X, Meng X, Hua Y, Wang Z, Zhang Y, Huang W, Wang L, Yuan S, Zhang P, Gong H, Sun Y, Zhang Y, Liu Z, Dong X, Gai F, Huang Z, Zhu C, Guo J, Wang Z. Short-term dynamics of circulating tumor DNA predicting efficacy of sintilimab plus docetaxel in second-line treatment of advanced NSCLC: biomarker analysis from a single-arm, phase 2 trial. J Immunother Cancer 2022; 10:jitc-2022-004952. [PMID: 36600554 PMCID: PMC9730395 DOI: 10.1136/jitc-2022-004952] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 11/10/2022] [Indexed: 12/12/2022] Open
Abstract
OBJECTIVE Robust biomarker predicting efficacy of immunotherapy is limited. Circulating tumor DNA (ctDNA) sought to effectively monitor therapeutic response as well as disease progression. This study aims to investigate predictive role of ctDNA short-term dynamic change (6 weeks postimmunotherapy) in a single-arm, phase 2 trial of sintilimab plus docetaxel for previously treated advanced non-small cell lung cancer (NSCLC) patients. METHODS A total of 33 patients with advanced NSCLC with disease progression during or after any first-line treatment were prospectively enrolled between 2019 and 2020. Patients received sintilimab (200 mg, day 1, every 3 weeks) plus docetaxel (75 mg/m2, day 3, every 3 weeks) for 4-6 cycles, followed by maintenance therapy with sintilimab (200 mg, day 1, every 3 weeks) until disease progression or unacceptable toxic effects. Blood samples were prospectively collected at baseline, and after 2 cycles of treatment (6 weeks post-treatment). All samples were subjected to targeted next-generation sequencing with a panel of 448 cancer-related genes. The landscape of high-frequency genomic profile of baseline and 6th week was described. Major molecular characteristics in preselected genes of interest associated with response to second-line chemoimmunotherapy were analyzed. The curative effects and prognosis of patients were evaluated. RESULTS Patients with ctDNA clearance at 6th week had decreased tumor volume, while most patients with positive ctDNA at 6th-week experienced an increase in tumor volume. Positive 6th-week ctDNA was associated with significantly shorter progression-free survival (PFS) (91 vs NR days; p<0.0001) and overall survival (47 vs 467 days; p =0.0039). Clearance of clonal mutations and none new clonal formation at 6th week were associated with longer PFS (mPFS 89 vs 266 days, p =0.003). ctDNA clearance at 6th week was an independent risk factor for progression or death (HR=100 (95% CI 4.10 to 2503.00), p=0.005). CONCLUSION ctDNA status and ctDNA mutation clearance putatively serve as predictive biomarkers for sintilimab combined with docetaxel chemotherapy in pretreated advanced NSCLC patients.
Collapse
Affiliation(s)
- Xiao Han
- Department of Internal Medicine Oncology, Shandong Cancer Hospital and Institute, Jinan, Shandong, China
| | - Xiaoyong Tang
- Department of Internal Medicine Oncology, Shandong Cancer Hospital and Institute, Jinan, Shandong, China
| | - Hui Zhu
- Department of Internal Medicine Oncology, Shandong Cancer Hospital and Institute, Jinan, Shandong, China
| | - Dongyuan Zhu
- Department of Internal Medicine Oncology, Shandong Cancer Hospital and Institute, Jinan, Shandong, China
| | - Xiqin Zhang
- Department of Internal Medicine Oncology, Shandong Cancer Hospital and Institute, Jinan, Shandong, China
| | - Xiangjiao Meng
- Department of Radiation Oncology, Shandong Cancer Hospital and Institute Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China
| | - Ying Hua
- Department of Internal Medicine Oncology, Shandong Cancer Hospital and Institute, Jinan, Shandong, China
| | - Zhongtang Wang
- Department of Internal Medicine Oncology, Shandong Cancer Hospital and Institute, Jinan, Shandong, China
| | - Yan Zhang
- Department of Internal Medicine Oncology, Shandong Cancer Hospital and Institute, Jinan, Shandong, China
| | - Wei Huang
- Department of Internal Medicine Oncology, Shandong Cancer Hospital and Institute, Jinan, Shandong, China
| | - Linlin Wang
- Department of Internal Medicine Oncology, Shandong Cancer Hospital and Institute, Jinan, Shandong, China
| | - Shuanghu Yuan
- Department of Internal Medicine Oncology, Shandong Cancer Hospital and Institute, Jinan, Shandong, China
| | - Pinliang Zhang
- Internal Medicine Department, Shandong Cancer Hospital and Institute, Jinan, Shandong, China
| | - Heyi Gong
- Department of Internal Medicine Oncology, Shandong Cancer Hospital and Institute, Jinan, Shandong, China
| | - Yulan Sun
- Department of Internal Medicine Oncology, Shandong Cancer Hospital and Institute, Jinan, Shandong, China
| | - Yingjie Zhang
- Department of Internal Medicine Oncology, Shandong Cancer Hospital and Institute, Jinan, Shandong, China
| | - Zengjun Liu
- Internal Medicine Department, Shandong Cancer Hospital and Institute, Jinan, Shandong, China
| | - Xiaomeng Dong
- Medical Department, Amoy Diagnostics Co Ltd, Xiamen, Fujian, China
| | - Fei Gai
- Medical Department, Amoy Diagnostics Co Ltd, Xiamen, Fujian, China
| | - Zhan Huang
- Medical Department, Amoy Diagnostics Co Ltd, Xiamen, Fujian, China
| | - Changbin Zhu
- Medical Department, Amoy Diagnostics Co Ltd, Xiamen, Fujian, China
| | - Jun Guo
- Department of Internal Medicine Oncology, Shandong Cancer Hospital and Institute, Jinan, Shandong, China
| | - Zhehai Wang
- Department of Internal Medicine Oncology, Shandong Cancer Hospital and Institute, Jinan, Shandong, China
| |
Collapse
|
5
|
Yuan J, Chen W, Wang L, Cao C, Song X, Zhao J, Gai F, Dong H, Zhu C, Shi H. 1248P Identification of Epstein-Barr virus (EBV)-associated gastric cancer at RNA-level by evaluating transcriptional status of seven EBV crucial genes. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.1366] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
6
|
Long C, Li K, Liu Z, Zhang N, Xing X, Xu L, Gai F, Che N. Real-world analysis of the EGFR mutation detection in plasma ctDNA from patients with non-small cell lung cancer. J Clin Oncol 2022. [DOI: 10.1200/jco.2022.40.16_suppl.e21069] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e21069 Background: Plasma sample has emerged as a promising surrogate sample for EGFR mutation detection in advanced non-small cell lung cancer (NSCLC). In clinical practice, whether EGFR variants in pretreatment plasma ctDNA of advanced lung cancer can predict prognosis in addition to guiding targeted therapy remains to be further explored. Methods: In this study, we retrospectively enrolled 315 NSCLC patients from Beijing Chest Hospital, 94.9% of whom were in stage IIIB-IV. EGFR gene mutation data from tissue detected by ARMS-PCR (Amoy Diagnostics, Xiamen, China) and paired plasma samples within one month of admission detected by SuperARMS-PCR (Amoy Diagnostics, Xiamen, China) were collected. The patients’ clinicopathological characteristics and treatment information were also collected for further analysis. Differences in PFS of targeted therapy between patients with positive and negative pretreatment plasma ctDNA EGFR mutation were compared. Results: EGFR-positive rate of tissue and plasma ctDNA was 65.1% (205/315) and 43.8% (138/315), respectively. L858R, 19-DEL, T790M, G719X, 20-INS, and L861Q mutations were detected in both samples. The sensitivity, specificity, PPV, NPV and concordance of ctDNA detection was 65.4%,96.4%, 97.1%, 59.9%, and 76.2%, respectively. In the study, patients’ pathological subtype was the factor affected plasma ctDNA EGFR alteration detection accuracy. The concordance in adenocarcinoma patients was obviously higher than that in non-adenocarcinoma (p = 0.02). 92 treatment naïve advanced patients with tissue EGFR mutation were received first and second-generation EGFR tyrosine kinase inhibitors (TKIs) therapies. 59.8% (55/92) patients also had EGFR mutation in plasma ctDNA, 40.2% (37/92) patients had no detectable EGFR mutations in plasma ctDNA. The median PFS in plasma ctDNA EGFR positive patients was 7.0 months versus 14.0 month in plasma ctDNA EGFR negative patients, with significantly difference (p = 0.004). Conclusions: Plasma sample could be a surrogate sample for molecular test when tissue sample was unavailable. The poor prognosis was observed in treatment naïve advanced NSCLC patients with baseline plasma EGFR mutation.
Collapse
Affiliation(s)
- Chaolian Long
- Department of Pathology, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China
| | - Kun Li
- Department of Pathology, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China
| | - Zichen Liu
- Department of Pathology, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China
| | - Nana Zhang
- Department of Pathology, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China
| | - Xuya Xing
- Department of Pathology, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China
| | - Liming Xu
- Department of Medical, Amoy Diagnostics, Xiamen, China
| | - Fei Gai
- Department of Medical, Amoy Diagnostics, Xiamen, China
| | - Nanying Che
- Department of Pathology, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China
| |
Collapse
|
7
|
Kang N, Wang Z, Gai F, Su W, Shen D, Wang J. Molecular classification of endometrial cancer of Chinese population. J Clin Oncol 2022. [DOI: 10.1200/jco.2022.40.16_suppl.e17623] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e17623 Background: Endometrial cancer (EC) is one of the most prevalent gynecologic tumors. Current diagnosis and treatment of EC no longer rely solely on traditional histopathological classification. Nevertheless, molecular classification of EC demonstrated clear prognostic value and may guide clinical decision. Methods: In this study, archived tissue specimens from 240 EC patients from Department of Pathology, Peking University People’s Hospital. Four subtypes [POLE ultramutated (POLE mut), microsatellite instability high (MSI-H), copy number low (CNL), and copy number high (CNH)] were stratified by next-generation sequencing (NGS) panel (Amoy Diagnostics, Xiamen, China) targeting POLE, TP53, BRCA1, and BRCA2 genes and microsatellite instability (MSI) status. Immunohistochemistry (IHC) was applied to detect the expression of P53, MMR and other related proteins. Results: Distribution of the EC subtypes in 240 patients was 13 (5.42%) of POLE mut, 36 (15.00%) of MSI-H, 41 (17.08%) of CNH, and 150 (62.50%) of CNL. Compared to published results of EC subtypes in Caucasian including TCGA, ProMisE as well as TransPORTEC, real-world data on Chinese ECs displayed a significantly larger proportion of CNL. In addition, novel biomarkers such as DUSP1, MCF7 and BUB1, which were independent prognostic marker from our previous research were validated. Also, it was found that BRCA2 appeared to be more prevalent in EC than BRCA1. Further analysis revealed that the overall consistency for NGS-based and IHC-based TP53 abnormalities detection and MSI/MMR status assessment were as high as 87.5% and 100%, respectively. Conclusions: Chinese ECs have unique molecular characteristics. In order to perform accurate molecular typing of Chinese ECs, more molecular indicators that match the characteristics of the Chinese population need to be added to the existing classifiers. NGS-based panel is easy to operate and replicate with high accuracy. Thus, it is a viable alternative to IHC in EC molecular classification.
Collapse
Affiliation(s)
- Nan Kang
- Peking University People's Hospital, Beijing, China
| | - Zhiqi Wang
- Peking University People's Hospital, Beijing, China
| | - Fei Gai
- Department of Medical, Amoy Diagnostics, Xiamen, China
| | - Wenqing Su
- Department of Medical, Amoy Diagnostics, Xiamen, China
| | - Danhua Shen
- Peking University People's Hospital, Beijing, China
| | - Jianliu Wang
- Department of Gynecology and Obstetrics,Peking University People's Hospital, Beijing, China
| |
Collapse
|
8
|
Biasato I, Chemello G, Oddon SB, Ferrocino I, Corvaglia M, Caimi C, Resconi A, Paul A, van Spankeren M, Capucchio M, Colombino E, Cocolin L, Gai F, Schiavone A, Gasco L. Hermetia illucens meal inclusion in low-fishmeal diets for rainbow trout (Oncorhynchus mykiss): effects on the growth performance, nutrient digestibility coefficients, selected gut health traits, and health status indices. Anim Feed Sci Technol 2022. [DOI: 10.1016/j.anifeedsci.2022.115341] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
|
9
|
Dong Z, Gao J, Zhu F, Gai F, Su W, Liang Z, Tian X, Shi H. Analysis of genomic alterations in pan-cancer from a large real-world Chinese population. J Clin Oncol 2022. [DOI: 10.1200/jco.2022.40.16_suppl.10568] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
10568 Background: Effective targeted therapy sorely depends on comprehensive and precise genomic profiling. Besides, single nucleotide variations (SNVs) and InDels, gene fusions, as drivers and therapeutic targets of great importance, are not yet well characterized in Chinese patients. Methods: Formalin-fixed, paraffin-embedded (FFPE) tumor tissues from 1,384 pan-cancer patients were collected and sequenced using next-generation sequencing (NGS) targeting 40 cancer genes including SNV, fusion and assessing copy number variation (CNV) (AmoyDx HANDLE Classic Panel). qPCR and fluorescence in situ hybridization (FISH) were further applied to verify NGS detected fusion genes. Results: 1,384 patients were recruited including 890 lung cancers, 272 colorectal cancers, 174 gastric cancers, and 48 endometrial cancers. The prevalence of fusion genes (5.49%), including ALK-fusion (2.67%), ROS1-fusion (0.94%), RET-fusion (0.72%), NRG1-fusion (0.29%), and NTRK-fusion (0.07%), was nearly double the frequency of previously reported data from East Asians. Prevalence of fusion genes varied in different types of cancers. For instance, ALK (3.7%), ROS1 (1.5%), RET (1.0%) and NRG1 (0.2%) fusions were largely found in patients with non-small cell lung cancer (NSCLC), and were rarely detected in other cancer types. Further analysis of genomic alterations in fusion-positive patients revealed that, TP53 (21%) was the most frequently co-occurred mutated gene with ALK fusion, while RET fusions and ROS1 fusions were rarely accompanied by other mutated genes. In addition, two patients with RBPMS- NRG1 fusion were accompanied by BRAF and RB1 mutations, whereas no co-occurred mutation was found in patients with other partners of NRG1. Patients with inconsistent results of RNA-based NGS and FISH validation fusions are still being followed for treatment and survival, updated data will be available at the time of the presentation. Conclusions: Genomic alterations in real-world Chinese populations have specific characteristics, especially fusion genes. Further characterization of these variants is essential for clinics to guide appropriate targeted therapies.
Collapse
Affiliation(s)
- Zhouhuan Dong
- Department of Pathology, The Chinese PLA General Hospital, Beijing, China
| | - Jie Gao
- Department of Pathology, The Chinese PLA General Hospital, Beijing, China
| | - Fengwei Zhu
- Department of Pathology, The Chinese PLA General Hospital, Beijing, China
| | - Fei Gai
- Department of Medical, Amoy Diagnostics, Xiamen, China
| | - Wenqing Su
- Department of Medical, Amoy Diagnostics, Xiamen, China
| | - Zhixin Liang
- Department of Respiratory Medicine, The Chinese PLA General Hospital, Beijing, China
| | - Xiaodong Tian
- Department of Thoracic Surgery, The Chinese PLA General Hospital, Beijing, China
| | - Huaiyin Shi
- Department of Pathology, Chinese PLA General Hospital, Beijing, China
| |
Collapse
|
10
|
Tao H, Liu Z, Mu J, Gai F, Huang Z, Shi L. Concomitant novel ALK-SSH2, EML4-ALK and ARID2-ALK, EML4-ALK double-fusion variants and confer sensitivity to crizotinib in two lung adenocarcinoma patients, respectively. Diagn Pathol 2022; 17:27. [PMID: 35144623 PMCID: PMC8832643 DOI: 10.1186/s13000-022-01212-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/21/2021] [Accepted: 01/25/2022] [Indexed: 11/25/2022] Open
Abstract
Introduction Anaplastic lymphoma kinase (ALK) gene rearrangements, have been identified in approximately 2-7% of patients with lung adenocarcinoma (LUAD). However, co-occurrence of double ALK fusions in one patient was rare. Herein, we reported two Chinese female LUAD patients with confirmed double ALK fusion variants by next generation sequencing. Case presentation Case 1, a 38-year-old female was diagnosed as peripheral LUAD in left upper lobe with synchronous multiple intrapulmonary metastases (pT2N0M1b, stage IVa). And case 2, a 58-year-old female had left lower lobe primary LUAD and synchronous multiple lung metastases (pT4N2M1b, stage IVa). In both patients, tumor cells displayed strong expression of ALK protein. Genetic profiling by next generation sequencing showed both patients concurrently harbored two types of ALK rearrangements. Case 1 had an unreported ALK-SSH2/EML4-ALK double fusions, and case 2 had an another novel ARID2-ALK/EML4‐ALK double fusions. Both of these patients responded to ALK inhibitor crizotinib. Conclusions Our study reported two novel ALK fusion partners never reported, which expands the knowledge of ALK fusion spectrum and provides insight into therapeutic options for patients with double ALK fusions.
Collapse
Affiliation(s)
- Hong Tao
- Department of Oncology, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China
| | - Zhe Liu
- Department of Oncology, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China
| | - Jing Mu
- Department of Pathology, Beijing Key Laboratory for Drug Resistant Tuberculosis Research, Beijing Chest Hospital, Capital Medical University, Thoracic Tumor Research Institute, Beijing Tuberculosis, Beijing, China
| | - Fei Gai
- Department of Medical Business, Amoy Diagnostics Co., Ltd, Xiamen, China
| | - Zhan Huang
- Department of Medical Business, Amoy Diagnostics Co., Ltd, Xiamen, China
| | - Liang Shi
- Department of Oncology, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China.
| |
Collapse
|
11
|
Chen X, Li K, Liu Z, Gai F, Zhu G, Lu S, Che N. Abstract 558: Muti-gene ARMS PCR using both cfDNA and cfRNAin the supernatant of pleural effusion achieves rapid and accuracy driver gene mutations detection. Cancer Res 2021. [DOI: 10.1158/1538-7445.am2021-558] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background Pleural effusion from patients with advanced non-small cell lung cancer has been proved valuable for molecular analysis, especially when the tissue sample not available. However, simultaneous detection of multiple driver gene alterations especially the fusions is still challenging.
Methods In this study, 77 patients with advanced NSCLC and pleural effusion were enrolled, 49 of whom had matched tumor tissues. Supernatants, cell sediments, and FFPE cell blocks were prepared from pleural effusion samples for detection of driver alterations by a PCR-based 9-gene mutation detection kit.
Results In addition to mutations in EGFR, KRAS and HER2 detected in genomic DNA from cell sediments, FFPE cell blocks, and in cfDNA from supernatants, and fusions in ALK detected in RNA from cell sediments and FFPE cell blocks, fusions in ALK were also successfully detected in cfRNA from supernatants. Compared with matched tumor tissue, the supernatant showed the highest overall sensitivity (81.3%), with 81.5% for SNV/Indels by cfDNA and 80% for fusions by cfRNA, followed by FFPE cell blocks (71.0%) and the cell sediments (66.7%). Within the group of treatment-naïve patients or malignant cells observed in the cell sediments, supernatant showed higher overall sensitivity (89.5%, 92.3%) with both 100% for fusions. Based on the results, an optimized driver gene mutations detection procedure of pleural effusion is proposed. With the proposed procedure, an overall sensitivity 85.3% was achieved, with 82.1% for SNV/Indels and 100% for fusions.
Conclusions CfDNA and cfRNA derived from pleural effusion supernatant (PES) have been successfully tested with a PCR-based multi-gene detection kit. An optimized procedure could maximize clinical value of testing pleural effusion samples and has good potential for routine clinical application.
Citation Format: Xuejing Chen, Kun Li, Zichen Liu, Fei Gai, Guanshan Zhu, Shun Lu, Nanying Che. Muti-gene ARMS PCR using both cfDNA and cfRNAin the supernatant of pleural effusion achieves rapid and accuracy driver gene mutations detection [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 558.
Collapse
Affiliation(s)
| | - Kun Li
- 1Beijing Chest Hospital, Beijing, China
| | | | - Fei Gai
- 2Amoy Diagnostics Co., Ltd, Xiamen, China
| | | | - Shun Lu
- 3Shanghai Chest Hospital, Shanghai, China
| | | |
Collapse
|
12
|
Gariglio M, Dabbou S, Gai F, Trocino A, Xiccato G, Holodova M, Gresakova L, Nery J, Bellezza Oddon S, Biasato I, Gasco L, Schiavone A. Black soldier fly larva in Muscovy duck diets: effects on duck growth, carcass property, and meat quality. Poult Sci 2021; 100:101303. [PMID: 34280644 PMCID: PMC8318895 DOI: 10.1016/j.psj.2021.101303] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/25/2020] [Revised: 05/13/2021] [Accepted: 06/01/2021] [Indexed: 11/18/2022] Open
Abstract
The aim of the study was to evaluate the effects of partially defatted black soldier fly (Hermetia illucens, HI) larva meal on the carcass characteristics and meat quality of Muscovy ducks (Cairina moschata domestica). A total of 192 female ducks aged 3 d were divided between 4 dietary treatments (6 pens/treatment; 8 birds/pen), characterized by increasing levels of substitution of corn gluten meal with HI meal (0%, 3%, 6%, and 9%; HI0, HI3, HI6, and HI9, respectively), and reared until 50 days of age. Twelve birds/treatment (2 birds/pen) were slaughtered on d 51 to evaluate the slaughter traits (i.e., carcass, breast, thigh, and organs weights), carcass yield and meat quality. The slaughter weight, hot and chilled carcass weights, and abdominal fat weight showed a quadratic response to HI meal (minimum for the HI6 group, P < 0.05). Dietary HI meal inclusion did not influence the ultimate pH, the color, the proximate composition or the thiobarbituric acid reactive substances (TBARS) values in either the breast or thigh meat. The mineral profile of the meat was slightly affected by the dietary treatment, with a linear increase in the Cu content of the thigh meat (P < 0.05), whereas no differences were observed for Zn, Mn, or Fe. Dietary HI meal inclusion increased the saturated fatty acid rate in the thigh meat (maximum for the HI9 group, P < 0.05), and the monounsaturated and polyunsaturated fatty acid content in the breast meat (maximum for the HI0 and HI9 groups, respectively, P < 0.05). The ∑n-6/∑n-3 ratio decreased linearly in both the breast and thigh meat, with the HI9 group showing the lowest values (P < 0.05). Finally, the heavy metal concentrations were below the EU limits for poultry meat. To conclude, the inclusion up to 9% of partially defatted HI larva meal in the diet of Muscovy ducks did not affect the slaughter traits or the meat quality, although it did affect the meat fatty acid profile.
Collapse
Affiliation(s)
- M Gariglio
- Department of Veterinary Sciences, University of Turin, Largo Paolo Braccini 2, 10095 Grugliasco, Turin, Italy
| | - S Dabbou
- Center Agriculture Food Environment (C3A), University of Trento, via E. Mach 1, 38010 San Michele all'Adige, Italy; Research and Innovation Centre, Fondazione Edmund Mach, 38010 San Michele all'Adige, Italy
| | - F Gai
- Institute of Science of Food Production, National Research Council, Largo Paolo Braccini 2, 10095 Grugliasco, Turin, Italy
| | - A Trocino
- Department of Comparative Biomedicine and Food Science, University of Padua, Viale dell'Università 16, 35020 Legnaro, Padua, Italy
| | - G Xiccato
- Department of Agronomy, Food, Natural Resources, Animal, and Environment, University of Padua, Viale dell'Università 16, 35020 Legnaro, Padua, Italy
| | - M Holodova
- Institute of Animal Physiology, Center of Biosciences, Slovak Academy of Sciences, Soltesovej 4-6, 040 01 Kosice, Slovak Republic
| | - L Gresakova
- Institute of Animal Physiology, Center of Biosciences, Slovak Academy of Sciences, Soltesovej 4-6, 040 01 Kosice, Slovak Republic
| | - J Nery
- Department of Veterinary Sciences, University of Turin, Largo Paolo Braccini 2, 10095 Grugliasco, Turin, Italy
| | - S Bellezza Oddon
- Department of Agricultural, Forest and Food Sciences, University of Turin, Largo Paolo Braccini 2, 10095 Grugliasco, Turin, Italy
| | - I Biasato
- Department of Agricultural, Forest and Food Sciences, University of Turin, Largo Paolo Braccini 2, 10095 Grugliasco, Turin, Italy
| | - L Gasco
- Institute of Science of Food Production, National Research Council, Largo Paolo Braccini 2, 10095 Grugliasco, Turin, Italy; Department of Agricultural, Forest and Food Sciences, University of Turin, Largo Paolo Braccini 2, 10095 Grugliasco, Turin, Italy.
| | - A Schiavone
- Department of Veterinary Sciences, University of Turin, Largo Paolo Braccini 2, 10095 Grugliasco, Turin, Italy; Institute of Science of Food Production, National Research Council, Largo Paolo Braccini 2, 10095 Grugliasco, Turin, Italy
| |
Collapse
|
13
|
Duan J, Bai H, Sun Y, Gai F, Tian S, Xu W. Construction and validation of an eight-gene risk prediction model for stage II-IIIA lung adenocarcinoma. J Clin Oncol 2021. [DOI: 10.1200/jco.2021.39.15_suppl.e20553] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e20553 Background: Clinical characters cannot precisely evaluate long-term survival of patients with resectable lung adenocarcinoma. Genomics studies of lung adenocarcinoma (LUAD) have advanced our understanding of LUAD's biology. Thus, genomics-based robust models predicting survival outcome for patients with operatable LUAD needs to be investigated. Here, we aimed to identify new gene signatures to construct a risk prediction model via integrating Omics data from The Cancer Genome Atlas (TCGA) to better evaluate the long-term clinical outcome of LUAD patients. Methods: A cohort of one hundred and eighty-nine stage II-IIIA lung adenocarcinoma cases receiving tumor resection were screened out and downloaded from TCGA database. Tumor samples without survival information and genes with low or no expression were removed. Genes associated with cancer and immune were further narrowed down using a Master Panel Gene Set (Amoydx). Lasso-Cox regression analysis was used to screen gene-survival outcome, and then a risk prediction model was established. LUAD cases were divided into high-risk or low-risk groups as per the scores, to assess differential expressed genes and pathways. Results: A total of 8 most survival outcome related genes (CLEC7A, PAX5, XCR1, KRT7, PLCG1, DKK1, CLEC10A, IKZF3) were identified after Lasso-Cox regression analysis and used for model construction. The overall survival (OS), progression-free survival (PFS) and disease-free survival (DFS) from the subgroups within the high- and low-risk groups were assessed and showed significant prolonged in low-risk group, the hazard ratio (HR) of OS was 2.72 (95%CI: 2.04-3.61, P = 5.91e-12) in high-risk group. Hierarchical clustering analysis, gene ontology (GO) analysis, gene set enrichment analysis (GSEA), and gene set variation analysis (GSVA) revealed that genes involved in immune responses were significantly suppressed in high-risk group, while as genes involved in antioxidative metabolism were activated, which gave us a hint that immune-metabolism interaction might play a vital role in determining the distal survival outcome of LUAD. Conclusions: Our risk prediction model enables precise evaluation of long-term survival for patients with LUAD. Further, it provides a novel and comprehensive understanding of biological impacts on LUAD prognosis, which offers new insights for future development of precise diagnostic and therapeutic approaches.[Table: see text]
Collapse
Affiliation(s)
- Jianchun Duan
- Peking University School of Oncology, Beijing Cancer Hospital & Institution, Beijing, China
| | - Hua Bai
- State Key Laboratory of Molecular Oncology, Department of Medical Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
| | - Yiting Sun
- Peking University School of Oncology, Beijing Cancer Hospital & Institution, Beijing, China
| | - Fei Gai
- Department of Medical, Amoy Diagnostics, Xiamen, China
| | - Shenya Tian
- Department of Medical, Amoy Diagnostics, Xiamen, China
| | - Wenfang Xu
- Department of Bioinformatics, Amoy Diagnostics, Xiamen, China
| |
Collapse
|
14
|
Li M, Gai F, Chen H. MiR-30b-5p Influences Chronic Exercise Arthritic Injury by Targeting Hoxa1. Int J Sports Med 2021; 42:1199-1208. [PMID: 33930933 DOI: 10.1055/a-1342-7872] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Abstract
We identified the role of miR-30b-5p in chronic exercise arthritic injury. Rats with chronic exercise arthritic injury received treatment with miR-30b-5p antagomiR. H&E and Safranin O-fast green staining were performed. The levels of tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-1β) were detected. The binding relationship between homeobox A1 (Hoxa1) and miR-30b-5p was revealed. After manipulating the expressions of miR-30b-5p and/or Hoxa1 in chondrocytes, the viability, apoptosis and migration of chondrocytes were assessed. The levels of molecules were determined by qRT-PCR or Western blot. MiR-30b-5p antagomiR ameliorated articular cartilage lesion and destruction, reduced Mankin's score and the levels of TNF-α, IL-1β, miR-30b-5p, matrix metallopeptidase 13 (MMP-13), and cleaved caspase-3, and increased relative thickness and the levels of Hoxa1, Aggrecan and type II collagen (COLII) in model rats. MiR-30b-5p up-regulation decreased Hoxa1 level, viability, migration and induced apoptosis, whereas miR-30b-5p down-regulation produced the opposite effects. MiR-30b-5p up-regulation increased the levels of MMP-13 and cleaved caspase-3, but decreased those of Aggrecan and COLII in chondrocytes. However, the action of miR-30b-5p up-regulation on chondrocytes was reversed by Hoxa1 overexpression. In conclusion, miR-30b-5p is involved in cartilage degradation in rats with chronic exercise arthritic injury and regulates chondrocyte apoptosis and migration by targeting Hoxa1.
Collapse
Affiliation(s)
- Maoxun Li
- Department of Orthopaedics, The People's Hospital of Jimo.Qingdao, Qingdao, China
| | - Fei Gai
- Department of Radiotherapy, The People's Hospital of Jimo.Qingdao, Qingdao, China
| | - Hongyu Chen
- Department of Emergency, Qingdao West Coast New Area Central Hospital, Qingdao, China
| |
Collapse
|
15
|
Chen X, Li K, Liu Z, Gai F, Zhu G, Lu S, Che N. Multigene PCR using both cfDNA and cfRNA in the supernatant of pleural effusion achieves accurate and rapid detection of mutations and fusions of driver genes in patients with advanced NSCLC. Cancer Med 2021; 10:2286-2292. [PMID: 33656807 PMCID: PMC7982639 DOI: 10.1002/cam4.3769] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/26/2020] [Revised: 01/16/2021] [Accepted: 01/21/2021] [Indexed: 01/29/2023] Open
Abstract
Background Pleural effusion from patients with advanced non‐small cell lung cancer (NSCLC) has been proved valuable for molecular analysis, especially when the tissue sample not available. However, simultaneous detection of multiple driver gene alterations especially the fusions is still challenging. Methods In this study, 77 patients with advanced NSCLC and pleural effusion were enrolled, 49 of whom had matched tumor tissues. Supernatants, cell sediments, and cell blocks were prepared from pleural effusion samples for detection of driver alterations by a PCR‐based 9‐gene mutation detection kit. Results Mutations in EGFR, KRAS, and HER2 were detected in DNA and cfDNA, fusions in ALK was detected in RNA and cfRNA. Compared with matched tumor tissue, the supernatant showed the highest overall sensitivity (81.3%), with 81.5% for SNV/Indels by cfDNA and 80% for fusions by cfRNA, followed by cell blocks (71.0%) and the cell sediments (66.7%). Within the group of treatment‐naïve patients or malignant cells observed in the cell sediments, supernatant showed higher overall sensitivity (89.5% and 92.3%) with both 100% for fusions. Conclusions CfDNA and cfRNA derived from pleural effusion supernatant have been successfully tested with a PCR‐based multigene detection kit. Pleural effusion supernatant seems a preferred material for detection of multigene alterations to guide treatment decision of advanced NSCLC.
Collapse
Affiliation(s)
- Xuejing Chen
- Department of Pathology, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis And Thoracic Tumor Research Institute, Beijing, China
| | - Kun Li
- Department of Pathology, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis And Thoracic Tumor Research Institute, Beijing, China
| | - Zichen Liu
- Department of Pathology, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis And Thoracic Tumor Research Institute, Beijing, China
| | - Fei Gai
- Medical Department, Amoy Diagnostics Co., Ltd., Xiamen, China
| | - Guanshan Zhu
- Medical Department, Amoy Diagnostics Co., Ltd., Xiamen, China
| | - Shun Lu
- Department of Oncology, Shanghai Chest Hospital Shanghai Jiaotong University, Shanghai, China
| | - Nanying Che
- Department of Pathology, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis And Thoracic Tumor Research Institute, Beijing, China
| |
Collapse
|
16
|
Zhang H, Yang X, Li K, Wang J, Lv J, Li X, Zhang X, Qin N, Zhang Q, Wu Y, Ma L, Gai F, Hu Y, Zhang S. [A Real-world Study on the Assessment of Pathological Characteristics and Targeted Therapeutic Effect of Non-small Cell Lung Cancer Patients with Positive Driving Genes and High PD-L1 Expression]. Zhongguo Fei Ai Za Zhi 2021; 24:78-87. [PMID: 33478196 PMCID: PMC7936084 DOI: 10.3779/j.issn.1009-3419.2021.104.02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
背景与目的 驱动基因突变阳性患者行靶向治疗,驱动基因阴性但程序性死亡配体1(programmed death-ligand 1, PD-L1)高表达患者行免疫抑制剂治疗,是晚期非小细胞肺癌(non-small cell lung cancer, NSCLC)患者一线治疗的首选,但对于驱动基因阳性且PD-L1高表达患者的治疗选择仍值得探究。 方法 以315例NSCLC患者为研究对象,分析驱动基因阳性且PD-L1高表达患者的临床病理特征及靶向治疗疗效。 结果 本研究纳入的315例NSCLC患者中,驱动基因突变总阳性率为62.2%,PD-L1高表达率(≥50.0%)为11.2%,驱动基因阳性且PD-L1高表达的患者比例为10.7%。其中表皮生长因子受体(epidermal growth factor receptor, EGFR)突变、KRAS 突变、ALK融合、BRAF突变和MET 14外显子跳跃突变患者中均有PD-L1高表达,比例分别为7.8%(11/141)、18.2%(4/22)、23.1%(3/13)、50.0%(2/4)和100.0%(1/1)。EGFR突变且PD-L1高表达患者主要为Ⅳ期肺腺癌患者,KRAS突变且PD-L1高表达患者主要为有吸烟史的患者。其中详细跟踪了两例分别为ALK融合阳性且PD-L1高表达(90.0%)和EGFR L858R突变且PD-L1高表达(70.0%)患者的靶向治疗全过程,两例患者总生存期分别仅为5个月和2个月。 结论 NSCLC患者各驱动基因突变与PD-L1高表达共存的比例和临床病理特征有较大差异。发生敏感突变且PD-L1高表达的患者靶向治疗疗效和预后可能更差。
Collapse
Affiliation(s)
- Hui Zhang
- Department of Medical Oncology, Beijing Chest Hospital, Capital Medical University/Beijing Tuberculosis and Thoracic Tumor
Research Institute, Beijing 101149, China
| | - Xinjie Yang
- Department of Medical Oncology, Beijing Chest Hospital, Capital Medical University/Beijing Tuberculosis and Thoracic Tumor
Research Institute, Beijing 101149, China
| | - Kun Li
- Department of Pathology, Beijing Chest Hospital, Capital Medical University/Beijing
Tuberculosis and Thoracic Tumor Research Institute, Beijing 101149, China
| | - Jinghui Wang
- Department of Medical Oncology, Beijing Chest Hospital, Capital Medical University/Beijing Tuberculosis and Thoracic Tumor
Research Institute, Beijing 101149, China
| | - Jialin Lv
- Department of Medical Oncology, Beijing Chest Hospital, Capital Medical University/Beijing Tuberculosis and Thoracic Tumor
Research Institute, Beijing 101149, China
| | - Xi Li
- Department of Medical Oncology, Beijing Chest Hospital, Capital Medical University/Beijing Tuberculosis and Thoracic Tumor
Research Institute, Beijing 101149, China
| | - Xinyong Zhang
- Department of Medical Oncology, Beijing Chest Hospital, Capital Medical University/Beijing Tuberculosis and Thoracic Tumor
Research Institute, Beijing 101149, China
| | - Na Qin
- Department of Medical Oncology, Beijing Chest Hospital, Capital Medical University/Beijing Tuberculosis and Thoracic Tumor
Research Institute, Beijing 101149, China
| | - Quan Zhang
- Department of Medical Oncology, Beijing Chest Hospital, Capital Medical University/Beijing Tuberculosis and Thoracic Tumor
Research Institute, Beijing 101149, China
| | - Yuhua Wu
- Department of Medical Oncology, Beijing Chest Hospital, Capital Medical University/Beijing Tuberculosis and Thoracic Tumor
Research Institute, Beijing 101149, China
| | - Li Ma
- Department of Medical Oncology, Beijing Chest Hospital, Capital Medical University/Beijing Tuberculosis and Thoracic Tumor
Research Institute, Beijing 101149, China
| | - Fei Gai
- Amoy Diagnostics Co.,Ltd, Xiamen 361000, China
| | - Ying Hu
- Department of Medical Oncology, Beijing Chest Hospital, Capital Medical University/Beijing Tuberculosis and Thoracic Tumor
Research Institute, Beijing 101149, China
| | - Shucai Zhang
- Department of Medical Oncology, Beijing Chest Hospital, Capital Medical University/Beijing Tuberculosis and Thoracic Tumor
Research Institute, Beijing 101149, China
| |
Collapse
|
17
|
Tao H, Shi L, Zhou A, Li H, Gai F, Huang Z, Che N, Liu Z. Distribution of EML4-ALK fusion variants and clinical outcomes in patients with resected non-small cell lung cancer. Lung Cancer 2020; 149:154-161. [PMID: 33017727 DOI: 10.1016/j.lungcan.2020.09.012] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/11/2020] [Revised: 09/16/2020] [Accepted: 09/18/2020] [Indexed: 01/07/2023]
Abstract
OBJECTIVES The molecular profiles and prognosis of anaplastic lymphoma kinase (ALK) fusion and resectable non-small cell lung cancer (NSCLC) remain unclear. This study aimed to explore the distribution of ALK fusion variants and prognostic factors in patients with surgically resected NSCLC. MATERIAL AND METHODS Among the 93 ALK positive surgical patients screened by immunohistochemistry (IHC) or real-time polymerase chain reaction (RT-PCR), 63 patients were confirmed as ALK rearrangement by next-generation sequencing (NGS), including 55 cases of stage I-III and 8 cases of stage IV. Medical records were retrospectively reviewed, the distribution of ALK fusion variants and prognostic factors were analyzed. RESULTS All of the 55 early stage patients were histological adenocarcinoma. No other fusion types were found except for echinoderm microtubule-associated protein-like 4- anaplastic lymphoma kinase (EML4-ALK). EML4-ALK variant 1 (E13:A20; 25/55, 45.5 %) was the predominant variant type, followed by EML4-ALK variant 3 (E6:A20; 19/55, 34.5 %) and variant 2 (E20:A20; 8/55, 14.5 %). Concomitant mutations occurred in 22 patients (22/55, 40.0 %), which involved in 32 co-mutations from 12 kinds of mutated genes. TP53 mutations were most common in coexisting mutations (13/32, 40.6 %). TP53 mutations were less frequently occurred in variant 1 group (3/25, 12.0 %) than in non-variant 1 group (10/30, 33.3 %, P = 0.064). The median disease-free survival (DFS) of the 55 patients was 22.1 months, and the median overall survival (OS) was not mature at the time of analysis. Multivariable analysis showed that stage T3 and EML4-ALK variant 3 were independent prognostic factors for shorter DFS. Neither TP53 mutations nor any coexisting mutations were related to prognosis. CONCLUSIONS This study illustrated the patterns of EML4-ALK fusion variants and gene profiles in patients with resected NSCLC. Advanced T stage and EML4-ALK variant 3 were associated with worse prognosis. The role of TP53 mutations in prognosis is worthy of further study.
Collapse
Affiliation(s)
- Hong Tao
- Department of Oncology, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China
| | - Liang Shi
- Department of Oncology, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China
| | - Aoxue Zhou
- Department of Oncology, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China
| | - Hongxia Li
- Department of Oncology, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China
| | - Fei Gai
- Amoy Diagnostics Co., Ltd, Xiamen, China
| | - Zhan Huang
- Amoy Diagnostics Co., Ltd, Xiamen, China
| | - Nanying Che
- Department of Pathology, Beijing Key Laboratory for Drug Resistant Tuberculosis Research, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China.
| | - Zhe Liu
- Department of Oncology, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China.
| |
Collapse
|
18
|
Gao X, Nan X, Liu Y, Liu R, Zang W, Shan G, Gai F, Zhang J, Li L, Cheng G, Song L. Front Cover, Volume 41, Issue 3. Hum Mutat 2020. [DOI: 10.1002/humu.23994] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
| | | | | | - Rui Liu
- Novogene Co. Ltd. Beijing China
| | | | | | - Fei Gai
- Novogene Co. Ltd. Beijing China
| | | | - Lei Li
- Novogene Co. Ltd. Beijing China
| | | | | |
Collapse
|
19
|
Gao X, Nan X, Liu Y, Liu R, Zang W, Shan G, Gai F, Zhang J, Li L, Cheng G, Song L. Comprehensive profiling of BRCA1 and BRCA2 variants in breast and ovarian cancer in Chinese patients. Hum Mutat 2019; 41:696-708. [PMID: 31825140 DOI: 10.1002/humu.23965] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/01/2018] [Revised: 09/18/2019] [Accepted: 11/17/2019] [Indexed: 01/04/2023]
Abstract
The identification and interpretation of germline BRCA1/2 variants become increasingly important in breast and ovarian cancer (OC) treatment. However, there is no comprehensive analysis of the germline BRCA1/2 variants in a Chinese population. Here we performed a systematic review and meta-analysis on such variants from 94 publications. A total of 2,128 BRCA1/2 variant records were extracted, including 601 from BRCA1 and 632 from BRCA2. In addition, 414, 734, 449, and 307 variants were also recorded in the BIC, ClinVar, ENIGMA, and UMD databases, respectively, and 579 variants were newly reported. Subsequent analysis showed that the overall germline BRCA1/2 pathogenic variant frequency was 5.7% and 21.8% in Chinese breast and OC, respectively. Populations with high-risk factors exhibited a higher pathogenic variant percentage. Furthermore, the variant profile in Chinese is distinct from that in other ethnic groups with no distinct founder pathogenic variants. We also tested our in-house American College of Medical Genetics-guided pathogenicity interpretation procedure for Chinese BRCA1/2 variants. Our results achieved a consistency of 91.2-97.6% (5-grade classification) or 98.4-100% (2-grade classification) with public databases. In conclusion, this study represents the first comprehensive meta-analysis of Chinese BRCA1/2 variants and validates our in-house pathogenicity interpretation procedure, thereby providing guidance for further PARP inhibitor development and companion diagnostics in the Chinese population.
Collapse
Affiliation(s)
| | | | | | - Rui Liu
- Novogene Co. Ltd., Beijing, China
| | | | | | - Fei Gai
- Novogene Co. Ltd., Beijing, China
| | | | - Lei Li
- Novogene Co. Ltd., Beijing, China
| | | | | |
Collapse
|
20
|
Placha I, Ocelova V, Chizzola R, Battelli G, Gai F, Bacova K, Faix S. Effect of thymol on the broiler chicken antioxidative defence system after sustained dietary thyme oil application. Br Poult Sci 2019; 60:589-596. [PMID: 31195808 DOI: 10.1080/00071668.2019.1631445] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
1. The purpose of this study was to examine if the concentration of thymol as the main compound of Thymus vulgaris essential oil (TEO) influenced the antioxidant defence system in broilers. 2. Twenty-four broiler chickens were randomly divided at the day of hatching into three dietary treatment groups (0%, 0.05% and 0.1%, w/w TEO) with eight birds in each and were fed until four weeks of age. 3. Thymol content in plasma, duodenal wall and breast muscle significantly increased when 0.1% of thyme oil was added to the diet (P < 0.05). Thymol concentration in plasma significantly correlated with levels measured in the duodenal wall and feed (rs = 0.7857, P < 0.05; rs = 0.7647, P < 0.05). Superoxide dismutase (SOD) activity increased, and malondialdehyde (MDA) concentration decreased significantly (P < 0.05) in blood from chickens fed 0.1% TEO supplementation. Although the thymol concentration did not significantly decrease MDA amounts in breast muscle, a declining trend was observed. 4. The trial data confirmed the efficient absorption of thymol from the digestive tract into the systemic circulation, but only traces were found in breast muscle. Thymol content was sufficient for expressing its antioxidant properties in blood, but its low content in breast muscle was insufficient to significantly affect lipid oxidation and fatty acid composition.
Collapse
Affiliation(s)
- I Placha
- Centre of Biosciences, Slovak Academy of Sciences, Institute of Animal Physiology , Kosice , Slovak Republic
| | - V Ocelova
- Centre of Biosciences, Slovak Academy of Sciences, Institute of Animal Physiology , Kosice , Slovak Republic
| | - R Chizzola
- Institute of Animal Nutrition and Functional Plant Compounds, University of Veterinary Medicine Vienna , Vienna , Austria
| | - G Battelli
- Institute of Sciences of Food Production, Italian National Research Council , Milan , Italy
| | - F Gai
- Institute of Sciences of Food Production, Italian National Research Council , Grugliasco , Italy
| | - K Bacova
- Centre of Biosciences, Slovak Academy of Sciences, Institute of Animal Physiology , Kosice , Slovak Republic
| | - S Faix
- Centre of Biosciences, Slovak Academy of Sciences, Institute of Animal Physiology , Kosice , Slovak Republic
| |
Collapse
|
21
|
Henry MA, Gai F, Enes P, Peréz-Jiménez A, Gasco L. Effect of partial dietary replacement of fishmeal by yellow mealworm (Tenebrio molitor) larvae meal on the innate immune response and intestinal antioxidant enzymes of rainbow trout (Oncorhynchus mykiss). Fish Shellfish Immunol 2018; 83:308-313. [PMID: 30219384 DOI: 10.1016/j.fsi.2018.09.040] [Citation(s) in RCA: 25] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/26/2018] [Revised: 09/11/2018] [Accepted: 09/12/2018] [Indexed: 06/08/2023]
Abstract
The present study investigated the effects of 25 and 50% dietary inclusion of yellow mealworm, Tenebrio molitor (TM), larvae on the intestinal antioxidant enzymes, lipid peroxidation and immune system of rainbow trout, Oncorhynchus mykiss. Fish were fed for 90 days with a control diet (TM0) or with 2 test diets (TM25 and TM50) where 35 and 67% of the fishmeal was replaced by TM larvae meal respectively. At the end of the growth trial, humoral immune parameters were assessed in the sera of the fish and the activities of antioxidant enzymes were measured in intestine homogenates. The present results show a strong increase of the activity of the antioxidant intestinal enzymes and reduction of lipid peroxidation. Increased trypsin inhibition and faster antibacterial activity of the serum were also detected. These evidences could be due to the physiological similarities between the exoskeleton of parasites and insects. The present findings reinforce the previous results which revealed a positive effect of the dietary TM on rainbow trout growth and further confirm its adequacy for fishmeal partial replacement in aquafeed.
Collapse
Affiliation(s)
- M A Henry
- Laboratory of Fish Nutrition and Pathology, Institute of Marine Biology, Biotechnology and Aquaculture, Hellenic Centre for Marine Research, Aghios Kosmas, 16777, Elliniko, Greece.
| | - F Gai
- Institute of Science of Food Production, National Research Council, Largo Paolo Braccini 2, 10095, Grugliasco, Turin, Italy
| | - P Enes
- CIMAR/CIIMAR - Centro Interdisciplinar de Investigação Marinha e Ambiental, Universidade do Porto, Terminal de Cruzeiros do Porto de Leixões, Av. General Norton de Matos s/n, Matosinhos, Portugal
| | - A Peréz-Jiménez
- CIMAR/CIIMAR - Centro Interdisciplinar de Investigação Marinha e Ambiental, Universidade do Porto, Terminal de Cruzeiros do Porto de Leixões, Av. General Norton de Matos s/n, Matosinhos, Portugal; Departamento de Zoología, Facultad de Ciencias, Universidad de Granada, Campus Fuentenueva s/n, Granada, Spain
| | - L Gasco
- Department of Agricultural, Forest and Food Science, University of Turin, Grugliasco, 10095, Turin, Italy
| |
Collapse
|
22
|
Hao S, Yan Y, Huang W, Gai F, Wang J, Liu L, Wang C. C-phycocyanin reduces inflammation by inhibiting NF-κB activity through downregulating PDCD5 in lipopolysaccharide-induced RAW 264.7 macrophages. J Funct Foods 2018. [DOI: 10.1016/j.jff.2018.01.008] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022] Open
|
23
|
Biasato I, Gasco L, De Marco M, Renna M, Rotolo L, Dabbou S, Capucchio M, Biasibetti E, Tarantola M, Sterpone L, Cavallarin L, Gai F, Pozzo L, Bergagna S, Dezzutto D, Zoccarato I, Schiavone A. Yellow mealworm larvae (Tenebrio molitor) inclusion in diets for male broiler chickens: effects on growth performance, gut morphology, and histological findings. Poult Sci 2018; 97:540-548. [DOI: 10.3382/ps/pex308] [Citation(s) in RCA: 68] [Impact Index Per Article: 11.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/22/2016] [Accepted: 09/20/2017] [Indexed: 11/20/2022] Open
|
24
|
Feng Q, Gai F, Sang Y, Zhang J, Wang P, Wang Y, Liu B, Lin D, Yu Y, Fang J. A comparison of QuantStudio™ 3D Digital PCR and ARMS-PCR for measuring plasma EGFR T790M mutations of NSCLC patients. Cancer Manag Res 2018; 10:115-121. [PMID: 29403309 PMCID: PMC5783148 DOI: 10.2147/cmar.s148134] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023] Open
Abstract
Background The AURA3 clinical trial has shown that advanced non-small cell lung cancer (NSCLC) patients with EGFR T790M mutations in circulating tumor DNA (ctDNA) could benefit from osimertinib. Purpose The aim of this study was to assess the usefulness of QuantStudio™ 3D Digital PCR System platform for the detection of plasma EGFR T790M mutations in NSCLC patients, and compare the performances of 3D Digital PCR and ARMS-PCR. Patients and methods A total of 119 Chinese patients were enrolled in this study. Mutant allele frequency of plasma EGFR T790M was detected by 3D Digital PCR, then 25 selected samples were verified by ARMS-PCR and four of them were verified by next generation sequencing (NGS). Results In total, 52.94% (69/119) had EGFR T790M mutations detected by 3D Digital PCR. In 69 positive samples, the median mutant allele frequency (AF) was 1.09% and three cases presented low concentration (AF <0.1%). Limited by the amount of plasma DNA, 17 samples (AF <2.5%) and eight samples (T790M-) were selected for verification by ARMS-PCR. Four of those samples were verified by NGS as a third verification method. Among the selected 17 positive cases, ten samples presented mutant allele frequency <0.5%, and seven samples presented intermediate mutant allele frequency (0.5% AF 2.5%). However, only three samples (3/17) were identified as positive by ARMS-PCR, namely, P6 (AF =1.09%), P7 (AF =2.09%), and P8 (AF =2.21%). It is worth mentioning that sample P9 (AF =2.05%, analyzed by 3D Digital PCR) was identified as T790M- by ARMS-PCR. Four samples were identified as T790M+ by both NGS and 3D Digital PCR, and typically three samples (3/4) presented at a low ratio (AF <0.5%). Conclusion Our study demonstrated that 3D Digital PCR is a novel method with high sensitivity and specificity to detect EGFR T790M mutation in plasma.
Collapse
Affiliation(s)
- Qin Feng
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Pathology, Peking University Cancer Hospital & Institute
| | - Fei Gai
- Oncology Business Division, Beijing Novogene Bioinformatics Technology Co., Ltd
| | - Yaxiong Sang
- Oncology Business Division, Beijing Novogene Bioinformatics Technology Co., Ltd
| | - Jie Zhang
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Thoracic Oncology II, Peking University Cancer Hospital & Institute, Beijing, China
| | - Ping Wang
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Pathology, Peking University Cancer Hospital & Institute
| | - Yue Wang
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Pathology, Peking University Cancer Hospital & Institute
| | - Bing Liu
- Oncology Business Division, Beijing Novogene Bioinformatics Technology Co., Ltd
| | - Dongmei Lin
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Pathology, Peking University Cancer Hospital & Institute
| | - Yang Yu
- Oncology Business Division, Beijing Novogene Bioinformatics Technology Co., Ltd
| | - Jian Fang
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Thoracic Oncology II, Peking University Cancer Hospital & Institute, Beijing, China
| |
Collapse
|
25
|
Biasato I, Ferrocino I, Biasibetti E, Grego E, Schiavone A, Gasco L, Gai F, Cocolin L, Capucchio M. Modulation of Intestinal Microbiota, Morphology and Mucin Composition by Dietary Insect Meal Inclusion in Free-Range Chickens. J Comp Pathol 2018. [DOI: 10.1016/j.jcpa.2017.10.025] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
26
|
Zhong J, Li L, Wang Z, Bai H, Gai F, Duan J, Zhao J, Zhuo M, Wang Y, Wang S, Zang W, Wu M, An T, Rao G, Zhu G, Wang J. Potential Resistance Mechanisms Revealed by Targeted Sequencing from Lung Adenocarcinoma Patients with Primary Resistance to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs). J Thorac Oncol 2017; 12:1766-1778. [DOI: 10.1016/j.jtho.2017.07.032] [Citation(s) in RCA: 39] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/24/2017] [Revised: 06/19/2017] [Accepted: 07/20/2017] [Indexed: 11/30/2022]
|
27
|
Renna M, Schiavone A, Gai F, Dabbou S, Lussiana C, Malfatto V, Prearo M, Capucchio MT, Biasato I, Biasibetti E, De Marco M, Brugiapaglia A, Zoccarato I, Gasco L. Evaluation of the suitability of a partially defatted black soldier fly ( Hermetia illucens L.) larvae meal as ingredient for rainbow trout ( Oncorhynchus mykiss Walbaum) diets. J Anim Sci Biotechnol 2017; 8:57. [PMID: 28680591 PMCID: PMC5494141 DOI: 10.1186/s40104-017-0191-3] [Citation(s) in RCA: 131] [Impact Index Per Article: 18.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2016] [Accepted: 06/15/2017] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND Two trials were performed to evaluate a partially defatted Hermetia illucens (HI) larvae meal as potential feed ingredient in rainbow trout (Oncorhynchus mykiss Walbaum) diets. In the first trial, 360 trout (178.9 ± 9.8 g of mean initial body weight) were randomly divided into three experimental groups (4 tanks/treatment, 30 fish/tank). The fish were fed for 78 days with isonitrogenous, isolipidic and isoenergetic diets containing increasing levels of HI, on as fed basis: 0% (HI0, control diet), 25% (HI25) and 50% (HI50) of fish meal substitution, corresponding to dietary inclusion levels of 0, 20% and 40%. In the second trial, 36 trout (4 tanks/treatment, 3 fish/tank) were used to evaluate the in vivo apparent digestibility coefficients (ADC) of the same diets used in the first trial. RESULTS Survival, growth performance, condition factor, somatic indexes, and dorsal fillet physical quality parameters were not affected by diet. The highest dietary inclusion of HI larvae meal increased dry matter and ether extract contents of trout dorsal fillet. The use of HI larvae meal induced a decrease of valuable polyunsaturated fatty acids (PUFA) even if differences were only reported at the highest level of HI inclusion. The insect meal worsened the lipids health indexes of the same muscle. Dietary inclusion of insect meal did not alter the villus height of the fish. No differences were found among treatments in relation to ADC of ether extract and gross energy, while ADC of dry matter and crude protein were higher in HI25 if compared to HI50. CONCLUSIONS The obtained results showed that a partially defatted HI larvae meal can be used as feed ingredient in trout diets up to 40% of inclusion level without impacting survival, growth performance, condition factor, somatic indexes, dorsal fillet physical quality parameters, and intestinal morphology of the fish. However, further investigations on specific feeding strategies and diet formulations are needed to limit the observed negative effects of the insect meal on the FA composition of dorsal muscle.
Collapse
Affiliation(s)
- M. Renna
- Department of Agricultural, Forest and Food Sciences, University of Torino, Largo P. Braccini 2, 10095 Grugliasco, TO Italy
| | - A. Schiavone
- Department of Veterinary Sciences, University of Torino, Largo P. Braccini 2, 10095 Grugliasco, TO Italy
- Institute of Science of Food Production, National Research Council, Largo P. Braccini 2, 10095 Grugliasco, TO Italy
| | - F. Gai
- Institute of Science of Food Production, National Research Council, Largo P. Braccini 2, 10095 Grugliasco, TO Italy
| | - S. Dabbou
- Department of Veterinary Sciences, University of Torino, Largo P. Braccini 2, 10095 Grugliasco, TO Italy
| | - C. Lussiana
- Department of Agricultural, Forest and Food Sciences, University of Torino, Largo P. Braccini 2, 10095 Grugliasco, TO Italy
| | - V. Malfatto
- Department of Agricultural, Forest and Food Sciences, University of Torino, Largo P. Braccini 2, 10095 Grugliasco, TO Italy
| | - M. Prearo
- Veterinary Medical Research Institute for Piedmont, Liguria and Aosta Valley, Via Bologna 148, 10154 Torino, Italy
| | - M. T. Capucchio
- Department of Veterinary Sciences, University of Torino, Largo P. Braccini 2, 10095 Grugliasco, TO Italy
| | - I. Biasato
- Department of Veterinary Sciences, University of Torino, Largo P. Braccini 2, 10095 Grugliasco, TO Italy
| | - E. Biasibetti
- Department of Veterinary Sciences, University of Torino, Largo P. Braccini 2, 10095 Grugliasco, TO Italy
| | - M. De Marco
- Department of Veterinary Sciences, University of Torino, Largo P. Braccini 2, 10095 Grugliasco, TO Italy
| | - A. Brugiapaglia
- Department of Agricultural, Forest and Food Sciences, University of Torino, Largo P. Braccini 2, 10095 Grugliasco, TO Italy
| | - I. Zoccarato
- Department of Agricultural, Forest and Food Sciences, University of Torino, Largo P. Braccini 2, 10095 Grugliasco, TO Italy
| | - L. Gasco
- Department of Agricultural, Forest and Food Sciences, University of Torino, Largo P. Braccini 2, 10095 Grugliasco, TO Italy
- Institute of Science of Food Production, National Research Council, Largo P. Braccini 2, 10095 Grugliasco, TO Italy
| |
Collapse
|
28
|
Peiretti P, Gai F. Comparative Assessment of Lipid and Fatty Acids of Nine Crop Species During Plant Growth. ANIM NUTR FEED TECHN 2017. [DOI: 10.5958/0974-181x.2017.00022.1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
29
|
Biagini D, Gasco L, Rosato R, Peiretti P, Gai F, Lazzaroni C, Montoneri C, Ginepro M. Compost-sourced substances (SBO) as feedstuff additives in rabbit production. Anim Feed Sci Technol 2016. [DOI: 10.1016/j.anifeedsci.2016.02.005] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
|
30
|
Biasato I, De Marco M, Rotolo L, Renna M, Lussiana C, Dabbou S, Capucchio MT, Biasibetti E, Costa P, Gai F, Pozzo L, Dezzutto D, Bergagna S, Martínez S, Tarantola M, Gasco L, Schiavone A. Effects of dietaryTenebrio molitormeal inclusion in free-range chickens. J Anim Physiol Anim Nutr (Berl) 2016; 100:1104-1112. [DOI: 10.1111/jpn.12487] [Citation(s) in RCA: 77] [Impact Index Per Article: 9.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/04/2015] [Accepted: 01/10/2016] [Indexed: 11/28/2022]
Affiliation(s)
- I. Biasato
- Dipartimento di Scienze Veterinarie; Università degli Studi di Torino; Grugliasco Torino Italy
| | - M. De Marco
- Dipartimento di Scienze Veterinarie; Università degli Studi di Torino; Grugliasco Torino Italy
| | - L. Rotolo
- Dipartimento di Scienze Agrarie; Forestali e Alimentari; Università degli Studi di Torino; Grugliasco Torino Italy
| | - M. Renna
- Dipartimento di Scienze Agrarie; Forestali e Alimentari; Università degli Studi di Torino; Grugliasco Torino Italy
| | - C. Lussiana
- Dipartimento di Scienze Agrarie; Forestali e Alimentari; Università degli Studi di Torino; Grugliasco Torino Italy
| | - S. Dabbou
- Dipartimento di Scienze Agrarie; Forestali e Alimentari; Università degli Studi di Torino; Grugliasco Torino Italy
| | - M. T. Capucchio
- Dipartimento di Scienze Veterinarie; Università degli Studi di Torino; Grugliasco Torino Italy
| | - E. Biasibetti
- Dipartimento di Scienze Veterinarie; Università degli Studi di Torino; Grugliasco Torino Italy
| | - P. Costa
- Dipartimento di Scienze Veterinarie; Università degli Studi di Torino; Grugliasco Torino Italy
| | - F. Gai
- Istituto di Scienze delle Produzioni Alimentari (ISPA); CNR; Grugliasco Torino Italy
| | - L. Pozzo
- Istituto di Scienze delle Produzioni Alimentari (ISPA); CNR; Grugliasco Torino Italy
| | - D. Dezzutto
- Istituto Zooprofilattico Sperimentale del Piemonte; Liguria e Valle d'Aosta; Torino Italy
| | - S. Bergagna
- Istituto Zooprofilattico Sperimentale del Piemonte; Liguria e Valle d'Aosta; Torino Italy
| | - S. Martínez
- Departamento de Producción Animal; Universidad de Murcia; Murcia Spain
| | - M. Tarantola
- Dipartimento di Scienze Veterinarie; Università degli Studi di Torino; Grugliasco Torino Italy
- Istituto di Ricerche Interdisciplinari sulla Sostenibilità; Università degli Studi di Torino; Grugliasco Torino Italy
| | - L. Gasco
- Dipartimento di Scienze Agrarie; Forestali e Alimentari; Università degli Studi di Torino; Grugliasco Torino Italy
- Istituto di Scienze delle Produzioni Alimentari (ISPA); CNR; Grugliasco Torino Italy
| | - A. Schiavone
- Dipartimento di Scienze Veterinarie; Università degli Studi di Torino; Grugliasco Torino Italy
- Istituto di Ricerche Interdisciplinari sulla Sostenibilità; Università degli Studi di Torino; Grugliasco Torino Italy
| |
Collapse
|
31
|
Gisondi P, Amerio P, Amoroso GF, Antonucci VA, Bardazzi F, Buongiorno MR, Bruni P, Campanati A, Caproni M, Carlesimo M, Carrera CG, Cianchino G, Cimmino G, Costanzo A, Cozzani E, Dapavo P, D'amico D, De Simone C, Del Giglio M, Di Nuzzo S, Gai F, Galluccio AG, Goffredo A, Gualdi G, Guarneri C, Kokelj F, Lasagni C, Loconsole F, Longo V, Malagoli P, Miracapillo A, Mugheddu C, Parodi A, Pellegrino M, Peserico A, Piaserico S, Pistone G, Potenza C, Plumari A, Stingeni L, Strippoli D, Travaglino M, Girolomoni G. Optimization of systemic treatments for chronic plaque psoriasis. Recommendations for switching and transitioning. GIORN ITAL DERMAT V 2013; 148:1-10. [PMID: 24675369] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
AIM The aim of this study was to provide practical recommendations for optimizing the use of conventional and biological systemic treatments for moderate-severe chronic plaque psoriasis, particularly in case of transitioning and switching. METHODS A total number of 147 dermatologists from 33 different countries including Italy achieved consensus in providing practical recommendations for the use of conventional and biological treatments for moderate to severe psoriasis based on systematic literature review and/or expert opinion. RESULTS In general, the continuous treatment regimen should be preferred in order to achieve a complete and long-term control of psoriasis. However, the treatment could be stopped or the dose reduced in case of complete disease clearance. A conventional drug could be associated to biological treatment in selected cases. Transitioning and/or switching could be considered in case of inefficacy or intolerance. A period of wash up is required if transitioning or switching is due to safety issues. CONCLUSION This study provides practical suggestions for the optimal use of conventional and biological treatments for chronic plaque psoriasis.
Collapse
Affiliation(s)
- P Gisondi
- Clinica Dermatologica, Università degli Studi di Verona, Verona, Italia -
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
32
|
Peiretti P, Gai F, Rotolo L, Brugiapaglia A, Gasco L. Effects of tomato pomace supplementation on carcass characteristics and meat quality of fattening rabbits. Meat Sci 2013; 95:345-51. [DOI: 10.1016/j.meatsci.2013.04.011] [Citation(s) in RCA: 35] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2012] [Revised: 11/27/2012] [Accepted: 04/04/2013] [Indexed: 12/01/2022]
|
33
|
Peiretti P, Gai F, Tassone S. Fatty acid profile and nutritive value of quinoa (Chenopodium quinoa Willd.) seeds and plants at different growth stages. Anim Feed Sci Technol 2013. [DOI: 10.1016/j.anifeedsci.2013.04.012] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
34
|
Sicuro B, Piccinno M, Gai F, Abete M, Danieli A, Dapra F, Mioletti S, Vilella S. Food Quality and Safety of Mediterranean Sea Cucumbers Holothuria tubulosa and Holothuria polii in Southern Adriatic Sea. ACTA ACUST UNITED AC 2012. [DOI: 10.3923/ajava.2012.851.859] [Citation(s) in RCA: 33] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
35
|
Bono G, Gai F, Peiretti P, Badalucco C, Brugiapaglia A, Siragusa G, Palmegiano G. Chemical and nutritional characterisation of the Central Mediterranean Giant red shrimp (Aristaeomorpha foliacea): Influence of trophic and geographical factors on flesh quality. Food Chem 2012. [DOI: 10.1016/j.foodchem.2011.07.004] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
36
|
Daprà F, Gai F, Costanzo MT, Maricchiolo G, Micale V, Sicuro B, Caruso G, Genovese L, Palmegiano GB. Rice protein-concentrate meal as a potential dietary ingredient in practical diets for blackspot seabream Pagellus bogaraveo: a histological and enzymatic investigation. J Fish Biol 2009; 74:773-789. [PMID: 20735599 DOI: 10.1111/j.1095-8649.2008.02157.x] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/29/2023]
Abstract
Field and laboratory studies were conducted to evaluate the intestinal responses to partial replacement of fish meal with rice protein concentrate (RPC) in practical diets for blackspot seabream Pagellus bogaraveo. Two experimental diets were formulated to be isoproteic and isoenergetic with an increasing level of RPC (20 and 35%, respectively) and were tested against a fish meal-based control diet (RPC0). The diets showed similar features for growth performances and both intestinal histology and digestive enzymes. This study confirmed that RPC does not induce intestinal mucosa alterations in this fish. The dietary RPC supplement caused a significant increase in trypsin activity, whereas lipase activity was reduced.
Collapse
Affiliation(s)
- F Daprà
- Institute of Science of Food Production, Torino Division, National Research Council, Via L. da Vinci 44, Grugliasco (TO), Italy.
| | | | | | | | | | | | | | | | | |
Collapse
|
37
|
|
38
|
Palmegiano GB, Costanzo MT, Daprà F, Gai F, Galletta MG, Maricchiolo G, Micale V, Peiretti PG, Genovese L. Rice protein concentrate meal as potential dietary ingredient in practical diets for blackspot seabream (Pagellus bogaraveo). J Anim Physiol Anim Nutr (Berl) 2007; 91:235-9. [PMID: 17516945 DOI: 10.1111/j.1439-0396.2007.00697.x] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
The aim of this study was to evaluate the performances and the flesh quality of Pagellus bogaraveo fed with diets containing rice protein concentrate [RPC, 70% crude protein (CP) and 10% ether extract]. Three isoproteic and isoenergetic (CP 47%, 22 MJ/kg DM) diets were formulated with an increasing level of RPC: 0%, 20% and 35%. The fish (mean weight 75 g) from the Messina Straits were randomly distributed in 12 tanks (3 diets x 4 replications, 10 fish/tank). The daily ratio (1.5% of the fish biomass) was updated every 15 days. Biomass gain showed an opposite trend to the RPC diet inclusion. No differences appeared in the somatic indexes. Differences appeared between fatty acid profiles of the dorsal muscle. Fatty acid of series n-6 increased and fatty acid of series n-3 decreased in fillets of fish fed with increasing levels of RPC. The inclusion of RPC in the diets, as a partial replacement of fish meal (20%), is possible without affecting the growth performance and fillet quality.
Collapse
Affiliation(s)
- G B Palmegiano
- Institute of Science of Food Production, National Research Council, Grugliasco (TO), Italy
| | | | | | | | | | | | | | | | | |
Collapse
|
39
|
Peiretti P, Gai F. Chemical composition, nutritive value, fatty acid and amino acid contents of Galega officinalis L. during its growth stage and in regrowth. Anim Feed Sci Technol 2006. [DOI: 10.1016/j.anifeedsci.2006.01.007] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
40
|
Gasco L, Palmegiano G, Gai F, Daprà F, Sicuro B, Guo K, Zoccarato I. Use of rice protein concentrate in rainbow trout feeding: preliminary results. Italian Journal of Animal Science 2005. [DOI: 10.4081/ijas.2005.2s.591] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
|
41
|
|
42
|
|
43
|
Negrerie M, Gai F, Lambry JC, Martin JL, Petrich JW. Photoionization and dynamic solvation of the excited states of 7-azaindole. ACTA ACUST UNITED AC 2002. [DOI: 10.1021/j100121a032] [Citation(s) in RCA: 32] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
44
|
Chen Y, Gai F, Petrich JW. Single-Exponential Fluorescence Decay of the Nonnatural Amino Acid 7-Azatryptophan and the Nonexponential Fluorescence Decay of Tryptophan in Water. ACTA ACUST UNITED AC 2002. [DOI: 10.1021/j100059a039] [Citation(s) in RCA: 57] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
45
|
|
46
|
Gai F, Rich RL, Petrich JW. Monophotonic Ionization of 7-Azaindole, Indole, and Their Derivatives and the Role of Overlapping Excited States. J Am Chem Soc 2002. [DOI: 10.1021/ja00081a039] [Citation(s) in RCA: 45] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
47
|
Gai F, Rich RL, Petrich JW. Monophotonic Ionization of 7-Azaindole, Indole, and Their Derivatives and the Role of Overlapping Excited States. [Erratum to document cited in CA120:163221]. J Am Chem Soc 2002. [DOI: 10.1021/ja00098a076] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
48
|
Rich RL, Gai F, Lane JW, Petrich JW, Schwabacher AW. Using 7-Azatryptophan to Probe Small Molecule-Protein Interactions on the Picosecond Time Scale: The Complex of Avidin and Biotinylated 7-Azatryptophan. J Am Chem Soc 2002. [DOI: 10.1021/ja00107a016] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
49
|
Rich RL, Chen Y, Neven D, Negrerie M, Gai F, Petrich JW. Steady-state and time-resolved fluorescence anisotropy of 7-azaindole and its derivatives. ACTA ACUST UNITED AC 2002. [DOI: 10.1021/j100111a012] [Citation(s) in RCA: 58] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
50
|
|